EPIC Diabetes Conference in Aurora addresses unique needs of women with diabetes
The Children's Diabetes Foundation is holding its 8th annual EPIC Diabetes Conference on Saturday, May 3, 2025. EPIC stands for Empowering Patients for Individualized Care. The Conference brings together experts from various aspects of disease care and gives patients and their families the opportunity to get their questions answered. Topics covered at the conference include the latest in technology, research, and care of the disease.
"It's a conference that's really an educational opportunity for people living with diabetes and their supporters, could be family, friends, could be extended family coming together to learn more about diabetes," said Dr. Sarit Polsky, Director of the Pregnancy & Women's Health Clinic at the Barbara Davis Center.
Among the presentations, there will be one on the impact of diabetes on women over the course of their lives.
"Everyone who is diagnosed with diabetes before adolescence has to deal with some challenges due to pubertal growth and increased insulin resistance," Polsky explained. "Women, on top of that, have to deal with changes in their glucose levels related to where they are in their menstrual cycle."
Hormones associated with a woman's reproductive system can impact her glucose levels and insulin tolerance. She'll see extra highs and lows throughout her monthly cycle, but then also through pregnancy and menopause.
"Pregnancy poses very unique challenges. In pregnancy, we're caring for not just one person but two, so we want to make sure the health of both the mother and the child," Polsky said.
High glucose levels during pregnancy can lead to large babies born with high blood sugar. If not checked, high glucose levels can also cause miscarriage.
"You can have a happy healthy pregnancy. You just have to work harder than someone who doesn't have diabetes," Polsky said.
CBS
"I think a lot of women living with Type 1 diabetes, it can be a concern...on what's pregnancy going to look like? How am I going to deal with the hormonal changes?" said Sydney Lundgren, a Type 1 diabetic.
In the 18-years that Lundgren has been living with Type 1 diabetes, technology has transformed her care. She wears a continuous glucose monitor that regularly tells her what her blood sugar level is. She also wears an insulin pump which administers insulin when she needs it.
"I like to wear mine (devices) where you can see them for that very reason, I want people to come talk to me. I love talking about it," she said.
That kind of education is actually part of her job. Lundgren works for the Children's Diabetes Foundation, which is the fundraising arm for the Barbara Davis Center.
"I love getting to work with other people living with Type 1 every single day," she said with a smile.
As a woman living with Type 1, Lundgren deals with some extra highs and lows. She needs every bit of technology she can get to keep her blood sugar levels on an even keel.
I can tell where in my cycle I am based on what my blood sugar is," she confirmed.
Lundgren will face new challenges when she enters into menopause. Working with qualified doctors and getting thorough answers to her questions a long the way will be key to Lundgren's ongoing good health.
"I think education is a great way to be more supportive," she said.
LINK: For Tickets and Information for EPIC Diabetes Conference
The EPIC Diabetes Conference is Saturday, May 3, 2025 on the Anschutz Medical Campus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
‘Why is our ship leaving?': Mom and daughter stranded as Norwegian Epic breaks from port
Jamie Cisco and her daughter, Grace, were at the beach in Catania, Sicily, when they saw their cruise ship moving away from the port without them. They looked at each other with confusion. 'Grace was like, 'Why is our ship leaving?'' Cisco told USA TODAY. 'I was like, 'I don't know.' We were told we had till 5:30 to re-enter the ship to leave again.' The Norwegian Epic ship separated from the pier on May 30 during high winds, causing a guest to fall from the gangway into the water and leaving others stuck on shore. 'Our concern was always the person that fell in that they were OK … but the lack of communication was just completely unacceptable and uncalled for,' the Illinois resident said. Cisco was among a number of guests temporarily left behind – and it's not the only recent incident of its kind. The pair took the 10-day Mediterranean cruise to celebrate Cisco's 50th birthday. After leaving the beach, where the gusts were so strong they couldn't lay their blankets flat on the ground, they returned to the port, only receiving updates of the situation on board from other guests in a Facebook group. Cisco said Norwegian did not immediately communicate updates directly to guests who were on shore for most of the day. When they arrived, the cruise ship was gone. According to Cisco, a member of the Facebook group wrote that the port authority had ordered the vessel out of port, adding to their confusion. They walked the 15 to 20 minutes to town and back again, seeing a cruise line employee for the first time around 5:30 p.m., who told them to return two hours later. 'Some people opted just to stay there, but there was no water (and) there was very little shade,' she recalled. Cisco and her daughter also only had what they needed for a beach day. At one point, after she pulled a muscle in her leg while walking around Catania, they had to go searching for pain medicine. By around 7:15 p.m., the ship had made its way back to the port. 'And when they got permission to open the gates, it was just a free-for-all,' Cisco said. 'People were just pushing and shoving.' Back on board, she said the ship's crew warmly welcomed them back and the captain apologized over the speakers. The incident caused the ship to depart late from Catania, and Cisco said the captain announced the next morning that its planned stop in Naples had been canceled – between half an hour to an hour after they were scheduled to disembark. Was your cruise itinerary changed?: Here's what to do next A May 31 letter to guests, reviewed by USA TODAY, said the ship's mooring lines parted after three bollards on the pier broke amid 'unexpectedly strong gale-force winds.' 'After this incident, the Harbor Master ordered us to leave the port to wait offshore until the wind had calmed down,' the note read. Guests were given $100 in onboard credit per cabin, but Cisco said she and her daughter missed their $200 excursion in Naples booked outside the cruise line. She plans to submit a claim to her travel insurance provider. 'We get home late on Thursday, so I imagine on Friday I'll be spending a lot of time on the phone trying to get this sorted.' Norwegian also gave passengers a 10% future cruise credit, according to the letter Cisco received. 'During this interruption, our crew were actively attending to our guests until they were able to re-embark the ship,' a spokesperson for the cruise line told USA TODAY earlier this week. 'As always the safety of our guests and crew is our top priority.' Norwegian did not immediately share a comment on Cisco's experience. While those incidents are relatively rare, it's not the only one of its kind in recent years. Carnival Cruise Line's Carnival Magic ship hit a pier in Jamaica during windy weather in February 2024, forcing it to move away and temporarily leave guests on shore. Winds have also caused MSC Cruises and Cunard Line ships to break from their moorings. Meghan Walch, Director of Product at InsureMyTrip, said travelers should start by contacting their cruise line, which 'will likely (and hopefully) cover expenses that the travelers were forced to pay due to the ship drifting off its moorings.' In the event of a missed independent excursion like Cisco's, travel insurance itinerary change benefits can come in handy. 'Typically, the cruise line would have to make a change in the itinerary after departure, and there would need to be verification from the cruise line that there was a change in the itinerary,' Walch said in an email. 'So, there could be coverage for the missed excursion if there is proof from the cruise line, and all other requirements are met.' If the incident causes the ship to be late by the plan's required number of hours, travel delay benefits may take effect – if the policyholder paid for food, transportation or lodging during the delay. Injuries sustained from those kinds of incidents may also fall under emergency medical coverage. 'Again, it's important to not only know what the cruise line will cover – but travelers should also know what is covered under their specific travel insurance policy,' she added. Cisco had hoped to visit Sorrento and missed a scheduled limoncello tasting, but she ultimately took the inconvenience in stride. 'Thankfully, there's lots of limoncello in Italy.' Nathan Diller is a consumer travel reporter for USA TODAY based in Nashville. You can reach him at ndiller@ This article originally appeared on USA TODAY: What happened to guests on land when a cruise ship broke from port
Associated Press
a day ago
- Associated Press
Bullpen Launches Emerging Fund to Champion the Next Generation of Life Sciences Innovators
New investment initiative fuels high-potential startups across biotools, medtech, digital health, and therapeutics. 'BIO Week is our opportunity to strip away the noise and create a space where life science leaders can connect authentically, share candid insights, and forge the partnerships.'— Christiaan Engstrom, CEO of Bullpen. BOSTON, MA, UNITED STATES, June 4, 2025 / / -- Bullpen, a trusted community of life sciences dealmakers, today announced the launch of its Bullpen Emerging Fund, a bold initiative designed to back mission-driven startups that are redefining the future of health. Through capital investment, deep mentorship, and access to a close-knit network of expert operators and investors, the fund aims to turn today's early-stage breakthroughs into tomorrow's clinical realities. The Emerging Fund, available to accredited investors, invests in standout companies selected for Bullpen's On-Deck class—founders chosen not only for their science but for their grit, vision, and purpose. The 2025 cohort includes: - Chandima Bandaranayaka, CEO: Precision Quantomics, accelerating drug discovery and personalized pharmacotherapy through high-resolution molecular profiling. - David Mead, CEO: Terra Bioforge, harnessing synthetic biology to streamline biological production and accelerate therapeutic development. - Doug Cohen, CEO: IR Medtek, developing real-time, noninvasive cancer detection technologies that improve early diagnosis and patient outcomes. - Harsha Rajasimha, CEO: Jeeva Clinical Trials, delivering decentralized trial software that enhances patient access, retention, and diversity in clinical research. - Linda Tempelman, CEO: Persista Bio, advancing cell therapy solutions for chronic diseases, including a novel approach to treating Type 1 diabetes. Each of these founders will pitch during Bullpen's 'Money Ball' sessions, June 16–18 at BIO International, to an audience of mission-aligned investors and partners. More than a moment on stage, these pitches represent the culmination of rigorous preparation and the start of a meaningful growth journey. 'Bullpen was built on a simple idea: if you bring the right people together in the right way, the outcomes take care of themselves. BIO Week is our opportunity to strip away the noise and create a space where life science leaders can connect authentically, share candid insights, and forge the partnerships that will move this industry forward,' said Christiaan Engstrom, CEO of Bullpen. Further information on the Bullpen Emerging Fund may be obtained from Ray Jordan, managing director, Putnam Insights LLC, and initial investor in the fund through Elmstead Partners LLC. Jordan may be reached at [email protected]. Expert Coaching to Catalyze Success Behind each founder is a seasoned mentor: - Michael Hill, Global Head of Science Innovations, MedTech Head Coach, with a legacy of scaling clinical tools from bench to bedside. - Stella Vnook, CEO of Likarda and Therapies Head Coach, a biotech operator with deep experience in moving science-backed products through commercial launch. - John Bonham-Carter, BioTools Head Coach and angel investor, guiding early-stage science into successful enterprise with strategic insight and operational depth. Throughout the week, Bullpen will host engaging programming across Boston innovation hubs like Portal Innovations, SmartLabs, and EPAM Continuum. Key agenda highlights include: Agenda Highlights Include: - Investor interviews with leaders from Novo Nordisk, Cincytech, DigitalDx, Mayo Clinic, Riverside Partners, and others, with open Q&A in the Press Room following each session. - Thematic forums exploring pivotal industry issues such as: - AI in Healthcare: Exploring how artificial intelligence is reshaping patient care and discovery. - Patient Access: Breaking down barriers to get therapies to those who need them most. - Tech Transfer: Bridging academic science and commercial application. - Rare Disease: Elevating patient voices and rare innovation journeys. - Global Forums: Perspectives from Japan, Korea, Canada, and Australia spotlighting international innovation. - Women in VC and venture insights sessions, giving voice to underrepresented perspectives in capital formation and funding trends. As BIO Week wraps, Bullpen leaves behind more than a schedule, it strengthens a movement. One that champions science, centers people, and dares to do things differently. With the Emerging Fund as its catalyst, Bullpen is helping the next generation of health innovators go further, faster. About Bullpen: Founded on the mantra Find Someone to Help. Repeat., Bullpen is a volunteer-led, member-driven network designed to foster meaningful connections and accelerate innovation in life sciences. With no booths or sales pitches, Bullpen cultivates a space where authentic conversation drives real outcomes. Its members include public and private company leaders, VCs, strategics, accelerators, and non-profit executives dedicated to building the future of health. Media Inquiries: Madelyn De Los Santos Putnam Insights email us here Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Business Wire
a day ago
- Business Wire
Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025
PONTE VEDRA, Fla.--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today announced that members of its executive leadership team will be attending and participating in the upcoming BIO International Convention 2025, taking place June 16-19, 2025 in Boston. Cadrenal executives will participate in one-on-one meetings with investors and potential partners to provide key updates on the Company's strategic direction and clinical development of its lead asset, tecarfarin. Those interested in meeting with Cadrenal management should request a meeting through the Conference meeting portal or contact Investor Relations at cadrenal@ The BIO International Convention is the world's largest and most comprehensive biotechnology event, convening over 20,000 industry leaders from across the global life sciences ecosystem. About Cadrenal Therapeutics, Inc. Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing therapeutics for patients with cardiovascular disease. Cadrenal's lead investigational product is tecarfarin, a novel oral vitamin K antagonist anticoagulant that addresses unmet needs in anticoagulation therapy. Tecarfarin is a reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Although warfarin is widely used off-label for a number of indications, extensive clinical and real-world data have shown it can have significant, serious side effects. With tecarfarin, Cadrenal is advancing an innovative solution to address the unmet needs in anticoagulation therapy, aiming to reduce the clinical complexities of warfarin and capture value in a market with high demand for safer, more manageable treatment options. Cadrenal is pursuing a pipeline-in-a-product approach with tecarfarin. Tecarfarin received Orphan Drug designation (ODD) for advanced heart failure patients with implanted mechanical circulatory support devices, including Left Ventricular Assisted Devices (LVADs). The Company also received ODD and fast-track status for tecarfarin in end-stage kidney disease and atrial fibrillation (ESKD+AFib). Cadrenal is opportunistically pursuing business development initiatives with a longer-term focus on creating a pipeline of cardiovascular therapeutics. For more information, visit and connect with us on LinkedIn.
